JournalTOCs

Followed Journals

Journal you Follow: 0

Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Jurnals are published.
Already have an account? Sign In to see the journals you follow.

Most Followed Journals

Top Publishers

Top Subjects

EJRR - European Journal of Risk Regulation

[3 followers] Follow
Full-text available via subscription

Subscription journal
ISSN (Print) 1867-299X
Published by Lexxion Verlagsgesellschaft

[12 journals]

Book Reviews
- Abstract: EJRR 1 2013 Book Reviews 113
  Book Reviews
  The Book Reviews section will introduce you to the latest and most interesting books on a
  wide range of topics pertaining to the law and policy of risk regulation. EJRR Book Reviews
  will strive to be present in every edition and will accept reviews from all disciplines. For
  further information on the submission of reviews please contact the Book Reviews Editor at
  david.hornsby@wits.
  PubDate: Thu, 28 Feb 2013 16:53:09 +010
The HOB-vín Judgment: A Failed Attempt to Standardise the Visual Imagery, Packaging and Appeal ...
- Abstract: EJRR 1 2013 Case Notes 101
  Case Notes
  The HOB-vín Judgment: A Failed Attempt to Standardise the
  Visual Imagery, Packaging and Appeal of Alcohol Products
  Alberto Alemanno*
  EFTA Court, Case E-2/12, HOB-vín ehf. v. The State Alcohol and Tobacco Company of Iceland
  (ÁTVR)1
  National rules of a EEA State, such as those at stake in the present judgment, under
  which a State monopoly on the retail sale of alcohol, may refuse to accept for sale alcoholic
  beve
  PubDate: Thu, 28 Feb 2013 16:50:36 +010
Trade, Investment and Risk: Substantial Amendment of the EU Regulatory Framework on Medical ...
- Abstract: EJRR 1 2013 Reports 97
  ‘illegitimate’ counterfeiters, smugglers and organised
  criminals.” 24 Indeed British America Tobacco
  agreed to pay, under its 2010 cooperation agreement
  with the EU, a sum of 200 million USD over
  a period of 18 years to fund enforcement activities
  against illicit trade.25 This may be a tempting option
  for many governments looking for additional funds,
  notwithstanding the instruction of Article 5.3 of the
  FCTC and correspon
  PubDate: Thu, 28 Feb 2013 16:48:29 +010
Trade, Investment and Risk: The WHO Protocol to Eliminate Illicit Trade in Tobacco Products: A ...
- Abstract: EJRR 1 2013 Reports 91
  The WHO Protocol to Eliminate Illicit
  Trade in Tobacco Products:
  A Next Step in International Control of
  Tobacco Products
  Lukasz Gruszczynski*
  This report discusses the main provisions of the recently
  adopted WHO Protocol to Eliminate Illicit Trade in
  Tobacco Products. While recognizing the remarkable
  achievement of the global community in its efforts to
  curb illicit trade in tobacco products at the international
  level
  PubDate: Thu, 28 Feb 2013 16:46:17 +010
Trade, Investment and Risk: Issues Arising from the European Commission’s Proposal on Biofuels
- Abstract: EJRR 1 2013 Reports 87
  * Senior Associate, Fratini Vergano – European Lawyers, Brussels.
  1 Directive 98/70/EC of the European Parliament and of the Council
  of 13 October 1998 relating to the quality of petrol and diesel fuels
  and amending Council Directive 93/12/EEC (OJ L 350, 28.12.1998,
  p. 58), last amended by Commission Directive 2011/63/EU of 1 June
  2011 amending, for the purpose of its adaptation to technical progress,
  Directive 98/70/EC of the European
  PubDate: Thu, 28 Feb 2013 16:38:53 +010
Regulatory Impact Assessment: “Thence We Came Forth to Rebehold the Stars”: A First ...
- Abstract: 82 Reports EJRR 1 2013
  (regardless of whether an authorization was granted
  or not), or whether it should withhold data from applications
  that received a negative decision and / or
  from withdrawn dossiers.
  Another challenge will be to implement appropriate
  safeguards to protect patient confidentiality. As
  a patient organization representative stated during
  the 22 November workshop, patients can be highly
  protective of their personal health data and the
  PubDate: Thu, 28 Feb 2013 16:36:12 +010
Pharmaceuticals: The EU Makes Giant Strides towards the Proactive Publication of Clinical Trial Data
- Abstract: 80 Reports EJRR 1 2013
  mechanism by which perfluorinated substances are
  transferred from blood to milk is not completely
  known, even though it seems related to the strong
  bound of PFCs to proteins.
  For a recent comprehensive review on perfluorinated
  compounds in food in different countries (i.e.
  UK, Spain, Germany, Canada and Japan), see Picó
  et al.32
  3. Nanomaterials
  Growth of the application of nanotechnology products
  is expected in food
  PubDate: Thu, 28 Feb 2013 16:33:52 +010
Food: Emerging Food Chemical Contaminants from Industry Pollution
- Abstract: 76 Reports EJRR 1 2013
  for a service should have the right to be engaged,
  be given choices, and have their opinions heard concerning
  its use.
  In addition to public engagement, measures towards
  increased stakeholder transparency must address
  concerns over the wisdom of “playing God.” If
  scientists or industry are not seen as accountable for
  their actions, intended uses of the technology are not
  put forward, and amateurs are viewed as being able
  PubDate: Thu, 28 Feb 2013 16:31:24 +010
Biotechnology: Microbial Governance – The Ethical Challenge of Synthetic Biology
- Abstract: EJRR 1 2013 Reports 73
  Reports
  This part of the EJRR hosts reports in which our correspondents keep readers up to date on the most recent
  developments in different areas of risk regulation. Our aim is to fuel the debate and trigger future research on
  cutting-edge risk subjects. The Reports are organised under different policy sections. Further sections will be
  added at regular intervals. If you are interested in contributing to any of the existing sections, please contac
  PubDate: Thu, 28 Feb 2013 16:26:12 +010
The Role of the Discount Rate in Cost-Benefit Analysis Between Theory and Practice: A ...
- Abstract: EJRR 1 2013 The Role of the Discount Rate in Cost-Benefit Analysis 59
  The Role of the Discount Rate in Cost-Benefit
  Analysis Between Theory and Practice:
  A Comparative Survey
  Felice Simonelli*
  This study focuses on the role of the discount rate in cost-benefit analysis (CBA) of regulation,
  providing a systematic investigation into regulatory practice vis-à-vis the existing economic
  theories. In the first part, a quick survey of the main economic literature on
  PubDate: Thu, 28 Feb 2013 16:24:21 +010
Towards Principles-Based Approaches to Governance of Health-Related Research Using Personal Data
- Abstract: EJRR 1 2013 Approaches to Governance of Health-Related Research Using Personal Data 43
  Towards Principles-Based Approaches
  to Governance of Health-Related Research
  Using Personal Data
  Graeme Laurie* and Nayha Sethi**
  Technological advances in the quality, availability and linkage potential of health data for
  research make the need to develop robust and effective information governance mechanisms
  more pressing than ever before; they also lead us to question the
  PubDate: Thu, 28 Feb 2013 16:19:29 +010
Not Entirely Reliable: Private Scientific Organizations and Risk Regulation – The Case of ...
- Abstract: Not Entirely Reliable:
  Private Scientific Organizations and Risk
  Regulation – The Case of Electromagnetic Fields
  Gabriel Doménech Pascual*
  Private scientific organizations exert a great deal of influence in the regulation of some
  technological risks. The high level of expertise of their members is arguably a good reason
  for them to participate in making and monitoring risk regulations, in order to adjust these
  to scientific progress. Nevertheless, there are
  PubDate: Thu, 28 Feb 2013 16:15:28 +010
Nudge and the Manipulation of Choice
- Abstract: EJRR 1 2013 Nudge and the Manipulation of Choice 3
  Nudge and the Manipulation of Choice
  A Framework for the Responsible Use of the Nudge Approach
  to Behaviour Change in Public Policy
  Pelle Guldborg Hansen* and Andreas Maaløe Jespersen**
  In Nudge (2008) Richard Thaler and Cass Sunstein suggested that public policy-makers
  arrange decision-making contexts in ways to promote behaviour change in the interest of
  individual citizens as well as that of society. Howeve
  PubDate: Thu, 28 Feb 2013 16:13:29 +010
Editorial
- Abstract: The EJRR starts the year by publishing a set of timely research articles engaging with
  some of the most cutting-edge developments in the area of risk regulation: the normative
  debate surrounding the acceptability of behaviourally-informed regulation, the role
  of expertise in the regulation of electromagnetic fields, the governance of e-Health
  initiatives, and the controversial use of discount rate in Cost-Benefit regulatory analysis.
  At a time in which Harvard Law School
  PubDate: Thu, 28 Feb 2013 16:08:35 +010
Book Reviews
- Abstract: EJRR 4 2012 Book Reviews 631
  Book Reviews
  The Book Reviews section will introduce you to the latest and most interesting books on a
  wide range of topics pertaining to the law and policy of risk regulation. EJRR Book Reviews
  will strive to be present in every edition and will accept reviews from all disciplines. For
  further information on the submission of reviews please contact the Book Reviews Editor at
  david.hornsby@wits.
  PubDate: Wed, 12 Dec 2012 13:10:51 +010
On the Concept of Capacity of Exempted Insurance Institutions: Who’s next'
- Abstract: EJRR 4 2012 Case Notes 625
  On the Concept of Capacity of Exempted Insurance Institutions:
  Who’s next'
  Vadim Mantrov*
  Case C-82/10, European Commission v Ireland [2011] ECR I-00000
  Article 4 of the First Council Directive 73/239/EEC of 24 July 1973 on the coordination
  of laws, regulations and administrative provisions relating to the taking-up and pursuit
  of the business of direct insurance other than life assurance, as amended and repealed
  by the Solvenc
  PubDate: Wed, 12 Dec 2012 13:06:57 +010
No more Doubts about the Nature of Unit-Linked Products
- Abstract: EJRR 4 2012 Case Notes 621
  No more Doubts about the Nature of Unit-Linked Products
  Covadonga Díaz Llavona*
  Judgment of the Court (fi fth Chamber) of 1 March 2012 (reference for preliminary ruling),
  Case C—166/11: Ángel Lorenzo González Alonso v Nationale Nederlanden Vida Cía. de
  Seguros y Reaseguros, S.A.E. (Spain)**
  A contract concluded away from business premises, under which life assurance is offered
  in return for payment of a monthly premium to be inv
  PubDate: Wed, 12 Dec 2012 13:05:17 +010
Trade, Investment and Risk: Sustainability Requirements for Biofuels in the EU: A New Trade and ...
- Abstract: EJRR 4 2012 Reports 607
  IV. Costs of Misdiagnosis, Adverse Events,
  and Abuse
  To date, relatively little analysis has been conducted
  regarding the costs of misdiagnosis, adverse drug reactions
  with OTC products, and abuse of OTC products.
  The reason these areas remain unexplored is
  due to the diffi culty of obtaining data. Publicly available
  information on these areas is not suffi ciently
  detailed to attribute these instances to OTC drug use.
  The
  PubDate: Wed, 12 Dec 2012 13:02:18 +010
Pharmaceuticals: Switching Pharmaceutical Products from Prescription to Over-the-Counter: The ...
- Abstract: EJRR 4 2012 Reports 601
  Pharmaceuticals
  This section updates readers on the latest developments
  in pharmaceutical law, giving information on
  legislation and case law on various matters (such as
  clinical and pre-clinical trials, drug approval and marketing
  authorisation, the role of regulatory agencies)
  and providing analysis on how and to what extent
  they might affect health and security of the individual
  as well as in industry.
  Switching Pharmac
  PubDate: Wed, 12 Dec 2012 13:00:41 +010
Food: EU Health Claims Regulation and the Marketing of Functional Foods: A Regulatory Void?
- Abstract: EJRR 4 2012 Reports 577
  Food
  This section aims at updating readers on the latest
  developments of risk-related aspects of food law at EU
  level, giving information on legislation and case law
  on various matters, such as food safety, new diseases,
  animal health and welfare and food labelling.
  EU Health Claims Regulation and
  the Marketing of Functional Foods:
  A Regulatory Void?1
  Herman Lelieveldt* and Cris Boonen**
  This report evaluates the curr
  PubDate: Wed, 12 Dec 2012 12:51:08 +010